Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations
Work
Year: 2024
Type: article
Abstract: The triple combination of elexacaftor/tezacaftor/ivacaftor (ETI) has dramatically improved the outcome of people with Cystic Fibrosis (pwCF) with at least one F508del mutation. However, carriers of ra... more
Source: Pediatric Pulmonology
Institutions Istituto Giannina Gaslini, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Istituti di Ricovero e Cura a Carattere Scientifico, University of Parma
Cites: 21
Cited by: 1
Related to: 10
FWCI: 1.323
Citation percentile (by year/subfield): 79.53
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze